TIM-3 blockade has been shown to reinvigorate T cells in preclinical models, and several clinical trials (e.g., NCT04137900) are now testing TIM-3 and TIGIT inhibitors in combination with PD-1/PD-L1 blockade in advanced gynecologic cancers [148,149]. This evidence concerns the gene HAVCR2 and female reproductive organ cancer.